Progress in Drug Research: Volume 55

· Progress in Drug Research 55. knjiga · Birkhäuser
E-knjiga
336
Broj stranica
Ocjene i recenzije nisu potvrđene  Saznajte više

O ovoj e-knjizi

Hepatitis C virus (HCV) was first identified in 1989 as the etiologic agent of non-A, non-B hepatitis [1] and is currently recognized as the leading cause of chronic liver disease worldwide. In contrast to hepatitis B virus infection, in which only about 5% of adult infections become chronic, more than 80% of HCV-infected patients develop chronic hepatitis. Moreover, 20-50% of those persistently infected with HCV will develop liver cirrhosis and hepatocellu lar carcinoma (HCC) [2]. It is estimated that there are 10,000 deaths in the USA per year due to chronic liver failure or HCC [3]. In addition, HCV dis 25-50% of all liver transplants in US centers, and the ease is responsible for recurrence of HCV infection following liver transplantation is universal [4]. Typically, HCV disease emerges after a 10-20 year period during which symp toms, if they exist at all, are mild and non-specific. Although the prevalence varies greatly among different countries, it has been estimated that up to 170 million people (3% of the world's population), are infected with HCV [5]. A recent study in the USA found that 65% of all HCV-infected persons are 30 to 49 years old [6].

Ocijenite ovu e-knjigu

Recite nam šta mislite.

Informacije o čitanju

Pametni telefoni i tableti
Instalirajte aplikaciju Google Play Knjige za Android i iPad/iPhone uređaje. Aplikacija se automatski sinhronizira s vašim računom i omogućava vam čitanje na mreži ili van nje gdje god da se nalazite.
Laptopi i računari
Audio knjige koje su kupljene na Google Playu možete slušati pomoću web preglednika na vašem računaru.
Elektronički čitači i ostali uređaji
Da čitate na e-ink uređajima kao što su Kobo e-čitači, morat ćete preuzeti fajl i prenijeti ga na uređaj. Pratite detaljne upute Centra za pomoć da prenesete fajlove na podržane e-čitače.